Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
10-Year Return on Invested Incremental Capital (10-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 10-year.
AFT Pharmaceuticals's 10-Year ROIIC % for the quarter that ended in Mar. 2026 was 17.69%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
The industry rank for AFT Pharmaceuticals's 10-Year ROIIC % or its related term are showing as below:
NZSE:AFT's 10-Year ROIIC % is ranked better than 75.09% of 859
companies
in the Drug Manufacturers industry
Industry Median: 4.3
vs NZSE:AFT: 17.69
Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.
High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
Be Aware
It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.
AFT Pharmaceuticals 10-Year ROIIC % Related Terms
AFT Pharmaceuticals 10-Year ROIIC % Historical Data
* Premium members only.
The historical data trend for AFT Pharmaceuticals's 10-Year ROIIC % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NZSE:AFT vs ZTS, UTHR, VTRS: 10-Year ROIIC % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, AFT Pharmaceuticals's 10-Year ROIIC %, along with its competitors' market caps and 10-Year ROIIC % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
AFT Pharmaceuticals 10-Year ROIIC % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, AFT Pharmaceuticals's 10-Year ROIIC % distribution charts can be found below:
* The bar in red indicates where AFT Pharmaceuticals's 10-Year ROIIC % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** Annual data of NOPAT and Invested Capital was used to calculate 10-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.
AFT Pharmaceuticals (NZSE:AFT) has a 10-Year ROIIC % of 17.69 as of Mar. 2026. 10-Year ROIIC % measures the change in earnings as a percentage of change in investment over 10-year. View historical data on AFT Pharmaceuticals and its competitors. According to the industry distribution chart, AFT Pharmaceuticals ranks #214 out of 859 companies in the Drug Manufacturers industry, placing it in the top 24.9%.
Is AFT Pharmaceuticals' 10-Year ROIIC % too high?
AFT Pharmaceuticals' current 10-Year ROIIC % is 17.69. The Drug Manufacturers industry median 10-Year ROIIC % is 4.30. AFT Pharmaceuticals' value of 17.69 is 311.4% above this industry median. Based on the distribution chart, AFT Pharmaceuticals ranks #214 out of 859 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, AFT Pharmaceuticals has a GF Score™ of 95/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does AFT Pharmaceuticals' 10-Year ROIIC % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, AFT Pharmaceuticals ranks #214 out of 859 companies for 10-Year ROIIC %. This places AFT Pharmaceuticals in the top 25% of its industry — outperforming the majority of peers. The industry median 10-Year ROIIC % is 4.30. AFT Pharmaceuticals' value of 17.69 is 311.4% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 10-Year ROIIC % for a Drug Manufacturers company?
The median 10-Year ROIIC % among Drug Manufacturers companies is 4.30, based on 859 companies in the industry. Companies in the top quartile (top 25%) have a 10-Year ROIIC % significantly above this median, while those in the bottom quartile fall well below. However, 10-Year ROIIC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. AFT Pharmaceuticals's current 10-Year ROIIC % of 17.69 is 311.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 10-Year ROIIC % mean?
A high 10-Year ROIIC % can signal that a stock is expensive relative to its fundamentals. 10-Year ROIIC % measures the change in earnings as a percentage of change in investment over 10-year. View historical data on AFT Pharmaceuticals and its competitors. For the Drug Manufacturers industry, the median 10-Year ROIIC % is 4.30 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. AFT Pharmaceuticals's current 10-Year ROIIC % is 17.69. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is AFT Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, AFT Pharmaceuticals (NZSE:AFT) is currently considered Fairly Valued. The stock's GF Value™ is NZ$4.20, compared to a current price of NZ$3.91 — trading 6.9% below its estimated fair value. The current 10-Year ROIIC % is 17.69 and 311.4% above the Drug Manufacturers industry median of 4.30. AFT Pharmaceuticals' overall GF Score™ is 95/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 10-Year ROIIC % calculated?
10-Year ROIIC % is calculated from a company's financial statements. For AFT Pharmaceuticals (NZSE:AFT), the current 10-Year ROIIC % is 17.69 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is AFT Pharmaceuticals (NZSE:AFT) Overvalued in 2026?
Based on GuruFocus' analysis, AFT Pharmaceuticals stock appears to be undervalued.
The current stock price of NZ$3.91 is trading 6.9% below its estimated GF Value™ of NZ$4.20.
GuruFocus considers AFT Pharmaceuticals to be Fairly Valued.
Key valuation signals for NZSE:AFT:
10-Year ROIIC %: 17.69
GF Value™: NZ$4.20 vs. price of NZ$3.91 (6.9% below fair value)
Industry Position: 311.4% above the Drug Manufacturers median (#214 of 859)
No single metric tells the full story. See the NZSE:AFT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
AFT Pharmaceuticals Ltd is a pharmaceutical distributor and developer of pharmaceutical intellectual property. Some of the products of the organization are Maxigesic dose forms, Capsaicin creams, Crystaderm, Kiwisoothe, Micolette, and others. The group has four operating segments based on geographical location being Australia, New Zealand, Asia, and the Rest of the world. It generates the majority of the revenue from Australia, which includes the sales and distribution activity relating to the Australian market.
95GF Score
Get the complete analysis for NZSE:AFT
10-Year ROIIC % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NZSE:AFT has been successfully added to your 
